Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Correction: Director Dealing and CLN Conversion

12 Nov 2020 07:00

RNS Number : 0361F
IQ-AI Limited
12 November 2020
 

IQ-AI Ltd

("IQ-AI" or the "Company")

Correction to Director Dealing and Conversion of Loan Notes Announcement

The following amendments have been made to the "Director Dealing and Conversion of Loan Notes" announcement released on 11 November at 07:00.

 

The original announcement stated that IQ-AI Ltd has received a conversion notice from Free Association Books Limited, converting £40,000 convertible loan notes and the £13,500 associated interest, into 3,566,666 Ordinary Shares. This should have been 3,566,667 Ordinary Shares. It also stated that Trevor Brown will be directly and indirectly interested in 47,557,403 Ordinary Shares, representing approximately 29.63 per cent. of the Company's enlarged issued ordinary share capital. This should have been 47,527,403 Ordinary Shares, representing approximately 29.61 per cent. of the Company's enlarged issued ordinary share capital.

All other details remain unchanged. The full amended text is shown below.

IQ-AI Ltd has received a conversion notice from Free Association Books Limited, converting £40,000 convertible loan notes and the £13,500 associated interest, issued in November 2015, at a price of 1.5 pence, into 3,566,667 Ordinary Shares. Free Association Books Limited ("FAB") is a company in which Trevor Brown, who is CEO of IQ-AI, has an interest. The Company has now fully converted all of the November 2020 convertible loan notes.

 

In addition, the Company has also received a conversion notice from Trevor Brown, converting £200,000 convertible loan notes and the £20,000 associated interest, issued in March 2018, at a price of 2 pence, into 11,000,000 Ordinary Shares.

 

In total, Trevor Brown will indirectly or directly be issued a total of 14,566,667 Ordinary Shares (the "CLN Shares"). In addition, Trevor Brown and FAB has in total sold 10,450,030 Ordinary Shares in the Company.

 

Following the above transactions, Trevor Brown will be directly and indirectly interested in 47,527,403 Ordinary Shares, representing approximately 29.61 per cent. of the Company's enlarged issued ordinary share capital. It is expected that the CLN Shares will commence trading on or around 17 November 2020 ("Admission").

 

Following Admission, the Company will have 160,522,649 ordinary shares of 0.01p each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 160,522,649.

 

The above figure of 160,522,649 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

-ENDS-

For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Trevor Brown

2

Reason for the notification

a)

Position/status

CEO

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

IQ-AI Ltd

b)

LEI

213800SPW48XRJS2QH57

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrumentIdentification code

Ordinary Shares of 1p eachISIN: JE00BD4H0R42

b)

Nature of the transaction

Sale of shares

c)

Price(s) and volume(s)

£0.17

75000

£0.15

75000

£0.15

75000

£0.14

1000000

£0.15

75000

£0.14

1000000

£0.11

1000000

£0.11

1000000

£0.15

1150030

£0.17

500000

 

 

d)

 

 

Aggregated information- Aggregated volume- Price

£0.11

4000000

 

 

N/A

e)

Date of the transaction

10 November 2020

f)

Place of the transaction

N/A

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Trevor Brown

2

Reason for the notification

a)

Position/status

CEO

b)

Initial notification /Amendment

Amendment to prior notifications

Late notification by selling broker

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

IQ-AI Ltd

b)

LEI

213800SPW48XRJS2QH57

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrumentIdentification code

Ordinary Shares of 1p eachISIN: JE00BD4H0R42

b)

Nature of the transaction

Sale of shares

c)

Price(s) and volume(s)

500000 Ordinary Shares at a price of £0.12 per share

d)

Aggregated information- Aggregated volume- Price

N/A

e)

Date of the transaction

10 November 2020

f)

Place of the transaction

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRBBBFTMTJBBRM
Date   Source Headline
18th Aug 202311:20 amRNSIB & GE HealthCare Enter into Commercial Agreement
17th Aug 20237:00 amRNSHalf-year Report
19th Jul 20237:00 amRNSImaging Biometrics Installs IB Nimble™ For MCW
13th Jul 20237:00 amRNSOrphan Drug Designation for GaM in Pediatric GBM
27th Jun 20237:00 amRNSStudies Show GaM Inhibits Pediatric Tumor Growth
23rd May 202311:02 amRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
3rd May 20234:14 pmRNSNotice of AGM
26th Apr 20237:00 amRNSFinal Results
28th Feb 20233:52 pmRNSOrphan Drug Designation Status
13th Jan 20232:05 pmRNSSecond Price Monitoring Extn
13th Jan 20232:00 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
10th Jan 20237:00 amRNSLetter to Shareholders
2nd Dec 202211:11 amRNSHolding in Company
25th Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSLetter to Shareholders
26th Sep 20227:00 amRNSIssue of Warrants to Employees
16th Aug 20224:40 pmRNSSecond Price Monitoring Extn
16th Aug 20224:35 pmRNSPrice Monitoring Extension
16th Aug 20229:28 amRNSHalf-year Report
3rd Aug 20221:01 pmRNSTR1 - Notification of Major Holdings
11th Jul 20227:00 amRNSImaging Biometrics Announces Channel Partnership
31st May 202211:05 amRNSSecond Price Monitoring Extn
31st May 202211:00 amRNSPrice Monitoring Extension
31st May 20228:00 amRNSSubmission of FDA 510(k) Application for IB Zero G
30th May 202210:47 amRNSResult of AGM
5th May 20223:00 pmRNSNotice of AGM
3rd May 20222:21 pmRNSIB Broadens Quantitative Mapping
28th Apr 20225:52 pmRNSFinal Results
9th Mar 20223:08 pmRNSIQAI’s Sponsored Phase I Clinical Trial is Open
28th Feb 202211:12 amRNSTotal Voting Rights
8th Feb 20227:00 amRNSIssue of shares to Mayo Clinic
27th Jan 20227:00 amRNSImaging Biometrics LLC - Letter to Shareholders
4th Jan 20229:27 amRNSDirector/PDMR Shareholding
17th Dec 20217:37 amRNSIQ-AI Prepares for Phase I Clinical Trial Launch
13th Dec 202110:32 amRNSDirector's Interest
11th Nov 20218:52 amRNSAgreement with St. Jude Children’s Hospital
2nd Nov 20218:19 amRNSMD ANDERSON ADOPTS IB CLINIC
28th Oct 20214:00 pmRNSLetter to Shareholders
7th Oct 20214:41 pmRNSSecond Price Monitoring Extn
7th Oct 20214:36 pmRNSPrice Monitoring Extension
7th Oct 20212:05 pmRNSSecond Price Monitoring Extn
7th Oct 20212:00 pmRNSPrice Monitoring Extension
7th Oct 202112:00 pmRNSPlacing
1st Oct 20218:17 amRNSCase Report on Clinical Value of IB Software
22nd Sep 20217:00 amRNSEU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING
17th Sep 20217:00 amRNSIB Software Chosen for Accuracy and Automation
10th Sep 20217:00 amRNSUpdate on Phase I Clinical Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.